Introduction DNA repair is central to the field of cancer biology, and it has important implications for cancer diagnosis and treatment. Cancer cells are often deficient in a normal DNA repair function, and this deficiency allows the tumor to develop…
Introduction Over the past 40 years, efforts to understand the underlying rules that govern the transformation of somatic cells into their malignant counterparts have led to the identification of discrete alterations in genes and gene products that, in combination, are…
Signaling: An Overview Intercellular communication is critical to embryonic development, tissue differentiation, and systemic responses to wounds and infections. These complex signaling networks are in large part initiated by growth factors. Such factors can influence cell proliferation in positive or…
Our understanding of the origins of cancer has changed dramatically over the past three decades, due in large part to the revolution in molecular biology that has altered the face of all biomedical research. Powerful experimental tools have been thrust…
You’re Reading a Preview Become a Clinical Tree membership for Full access and enjoy Unlimited articles Become membership If you are a member. Log in here
The individual with a newly diagnosed hematologic malignancy begins a journey with the urgent goal to cure the malignancy. That goal can be met for an ever-increasing number of these individuals, and hematopoietic cell transplant (HCT) plays an important role…
Introduction Patients with hematologic malignancies experience complex physical and psychosocial symptoms, affecting their quality of life (QOL). Patients may undergo specific high-risk procedures such as hematopoietic cell transplantations (HCTs) and chimeric antigen receptor T-cell (CAR-T-cell) therapies, which further predispose them…
Hemophagocytic Lymphohistiocytosis Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially life-threatening complication of autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, reported in 1% to 3.5% of patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL). In the ZUMA-1…
Epidemiology and Pathogenesis Beginning in 2017, there has been a steady increase in use of U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell products for refractory relapsed hematologic tumors. Various host factors like disease burden, pretreatment inflammation,…
Introduction T-cells genetically engineered to express a chimeric antigen receptor (CAR) that targets a specific tumor antigen have become a major clinical tool to treat several high-risk hematologic malignancies. Since the development of the first CAR T-cell in 1989, remarkable…